Intractable hiccups due to herpetic esophagitis in an immunocompromised patient  by Harris, John et al.
IDCases 4 (2016) 34–37Case Report
Intractable hiccups due to herpetic esophagitis in an
immunocompromised patient
John Harris *, Tukisa Smith, Jana Preis
SUNY/Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, United States
A R T I C L E I N F O
Article history:
Received 19 October 2015
Accepted 9 January 2016
Keywords:
Herpes simplex
Esophagitis
Hiccups
Immunocompromised
A B S T R A C T
Introduction: Herpes virus family’s association with visceral lesions is well established. Herpes simplex
virus presentations vary based on immune status. Intractable hiccups due to herpes simplex esophagitis,
to the best of our knowledge have been described twice in the literature. We present a 68 year-old
immunocompromised male with intractable hiccups for 10 months.
Case: 68 year-old male with end-stage renal disease and multiple myeloma presented with coffee
ground emesis and hiccups of ten months duration. A year earlier, he received cycles of bortezomib and
dexamethasone, remaining on lenalidomide. During chemotherapy, he developed pneumococcal
meningitis and subsequently intractable hiccups. Preceding admission, endoscopy showed duodenitis
and esophagitis. Proton-pump inhibitor therapy was initiated; however, biopsy was not performed.
During admission, hiccups often occurred every few seconds while off anti-emetics, persisting despite
therapy. Exam showed cachexia/temporal wasting, aphthous stomatitis and abdominal tenderness. MRI
of brain/spine, CT of neck, chest, abdomen and neurological evaluation were unremarkable. Endoscopy
revealed gastritis and esophagitis with mucosal tears. Biopsy revealed intra-nuclear inclusions with
multi-nucleated cells, consistent with herpes virus, later conﬁrmed as herpes simplex by
immunostaining. Hiccups and emesis resolved after of 2 days of intravenous acyclovir. 21 days of
treatment were completed with oral valacyclovir. He remained free of hiccups during the remaining
hospital stay and follow up.
This case illustrates an exceptionally rare presentation of herpetic esophagitis in an immunocom-
promised host. As novel immunotherapeutic/suppressive agents continue to emerge, the evolving role of
herpes virus prophylaxis and diagnosis of atypical presentations in new host populations is a topic of
growing importance.
 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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jo u rn al ho m epag e: ww w.els evier . c om / lo cat e/ idc rThe ﬁrst association of a member of the Herpes virus family and
visceral lesions was established in 1940 by Johnson [1]. Since then,
Herpes simplex virus (HSV) has played a well deﬁned role as the
etiologic agent in infectious processes throughout the GI tract, in
the immunocompromised, as well as immunocompetent host.
Within the GI tract, HSV-1 is most commonly associated with oral
and esophageal herpetic lesions, while HSV-2 is more commonly
associated with proctitis, most notably in the homosexual male
population. In a 2003 autopsy series of 1307 cases, the reported
incidence of herpetic esophagitis was 1.8%. Of the 24 cases of
herpes simplex esophagitis (HSE) identiﬁed, 18/23 (75%) were
associated with underlying malignancy some of whom received* Corresponding author. Tel.: +1 7705619205.
E-mail address: willistonharris@gmail.com (J. Harris).
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2214-2509/ 2016 Published by Elsevier Ltd. This is an open access article under the chemotherapy, while the remaining 5/23 (21%) cases were
associated with underlying immunocompromise or a condition
requiring immunosuppressive therapy. In many of these cases,
documented clinical symptoms of esophagitis were absent [2].
Among the immunocompromised population, HSV was most
commonly associated with esophagitis in bone marrow transplant
recipients not on antiviral prophylaxis. In a study of esophageal
infections in patients after bone marrow transplantation, HSV was
implicated as a sole pathogen or co-pathogen in 10/17 (58%) cases
of patients with ﬁndings on endoscopy [4]. In another study of 221
renal transplant patients, the diagnosis of HSV esophagitis was
made in 5 (2.2%) patients [5]. In the AIDs population, many of the
studies of herpetic esophagitis (HE) were carried out prior to the
introduction of effective anti-retroviral therapy (ART) and in one
prospective study of AIDs patients not on ART, HE occurred in 4 of
145 patients (2.5%) [6]. Although HSE is much more common in theCC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Image A. Endoscopic view: two shallow, friable linear ulcerations extending to the
gastro-esophageal junction, otherwise normal appearing mucosa.
Image B. (above): Esophageal mucosa with chronic inﬂammation and adjacent
necrotic tissue 100.
Image C. (above): Necrotic tissue with intranuclear inclusion-bearing cells 200.
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individual, most often representing primary infection. In a study of
immunocompetent individuals, the most common presenting
symptoms included acute odynophagia (76.3%), heartburn (50%)
and fever (44.7%) [3]. Intractable hiccups (singultus) due to herpes
simplex esophagitis, to the best of our knowledge has only been
described on 2 other occasions in the literature to date. Here we
present the case of a 68 y/o immunocompromised male who
presented with intractable hiccups for 10 months.
Case report
A 68 year old African American male with a history of
hypertension, end-stage renal disease and multiple myeloma
presented to the emergency department for evaluation of
recurrent coffee ground emesis associated with chronic hiccups
of ten months duration. The year prior, he was diagnosed with
multiple myeloma, completing nine cycles of bortezomib and
dexamethasone with poor response. Additional chemotherapy
with lenalidomide was initiated and continued until admission.
Ten months prior to admission, his chemotherapy was interrupted
due to an episode of pneumococcal meningitis after which he
developed intractable hiccups. He had multiple evaluations for
hematemesis, requiring several blood transfusions in the four
months prior to admission. Endoscopic ﬁndings were signiﬁcant
for duodenitis, esophagitis and he was treated with proton-pump
inhibitor therapy. However, a biopsy had never been performed.
During admission, hiccups occurred as often as every 2–3 s
while off chlorpromazine or ondansetron. In addition to hema-
temsis present on admission, he reported chronic abdominal pain
secondary to hiccups but notably absent were signs of dysphagia or
odynophagia. Review of systems was signiﬁcant for fatigue,
nausea, anorexia and weight loss. Physical exam was signiﬁcant
for cachexia, temporal wasting, aphthous stomatitis involving the
tongue and diffuse abdominal tenderness. Initial laboratory
studies were signiﬁcant for low hemoglobin (8.3 g/dL) and an
elevated BUN/Cr (16/3.8 mg/dL), consistent with end stage renal
disease. Initial imaging on admission included a chest X-ray which
was unremarkable. Throughout admission, his hiccups persisted
despite maximum dosing of ondansetron and chlorpromazine,
although with moderate improvement. Even as an outpatient,
during the prior ten months of oral chlorpromazine therapy his
hiccups never completely resolved. Inpatient neurological evalua-
tion and extensive imaging which included MRI of the brain/spine,
CT of soft tissue of the neck and CT of the chest and abdomen failed
to reveal any central process or obvious organic cause of vagus or
phrenic nerve irritation.
Given the persistent hematemesis despite proton pump
therapy, endoscopic evaluation was performed. In comparison to
endoscopic evaluation one week prior, which showed mild
duodenitis and severe diffuse esophagitis with shallow ulcerations
in a circumferential fashion at the gastro-esophageal (GE) junction,
repeat endoscopic ﬁndings included mild gastritis with persistent
duodenitis and severe diffuse esophagitis now with mucosal tears.
During this study, no biopsies were obtained secondary to
esophageal friability. Given the mucosal appearance, there were
initial concerns for eosinophilic esophagitis in which presumptive
treatment with corticosteroids were considered, however, only
symptomatic management was decided until repeat endoscopic
evaluation with biopsy could be performed (Images A–F).
Five days later repeat endoscopic evaluation with biopsies from
the middle and distal esophagus were performed. Pathology was
notable for numerous intranuclear inclusions with multinucleated
cells (see below) consistent with a viral process. Speciﬁc
immunostaining conﬁrmed the presence of herpes simplex virus
(not speciﬁc to type). Evaluation for concurrent HIV infection wasnegative by enzyme-linked immunosorbent assay (ELISA). Neither
cytomegalovirus polymerase chain reaction (PCR) nor IgM were
performed, although IgG was positive, indicating carrier status.
Intravenous acyclovir was promptly initiated in addition to
Image D. (above): Necrotic tissue with intranuclear inclusion-bearing cells 200.
Image E. Characteristic Herpes simplex intranuclear inclusions. Some cells are
mutinucleated 400.
Image F. Aphthous ulcers on tongue.
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ondansetron. Within two days, the patient reported complete
resolution of singultus and emesis. Given the patient’s response
with the addition of acyclovir, he no longer required anti-emetics
or chlorpromazine and completed a successful trial of oral intake
so after. After completing 5 days of intravenous acyclovir, he was
transitioned to oral valacyclovir, thus completing a 21-day course
of treatment as outpatient. Throughout the remaining hospital
course and brief outpatient follow up, he remained free of hiccups
and intractable vomiting. Unfortunately, long term follow up was
not possible as he expired soon after discharge, likely related to his
underlying malignancy.
Discussion
Herpes simplex virus is a member of the Herpesviridae family,
which contains linear, double stranded DNA surrounded by an
outer glycoprotein layer [7]. Although HSV-1 and HSV-2 are
genetically 70% homologous, HSV-1 has a greater propensity for
oral and GI infections. Although HSV as a cause of esophagitis has
been well described, this unique presentation of intractable
hiccups as in our case is exceedingly rare. Of the two cases
described in the literature, one an immunocompromised individual
with renal allograft rejection and the other, an immunocompetentindividual, who underwent thoracotomy and coronary bypass
[8,9]. Similar to our case, dysphagia and odynophagia were
notably absent in the case of the immunocompromised
individual described in the literature. However in our case, a
noteworthy difference was the duration of the hiccups, which
were consistently present for several months prior to presenta-
tion. Many causes of intractable or persistent hiccups have been
described in the literature. Among those included are various
metabolic, gastrointestinal, central nervous system, thoracic and
cardiovascular disorders. Irritation of the vagus and phrenic
nerve, malignancy, adverse drug reactions and psychogenic
causes has all been implicated [10,11]. Our patient received
extensive work up, including neuro-imaging and no other
obvious etiology of the hiccups was identiﬁed.
In immunocompromised populations, the predisposition of
HSV reactivation is in part related to deﬁcient cell mediated
immunity, which is thought to play a more important role than
humoral immunity in prevention of reactivation of herpes virus.
However, since multiple myeloma is characterized by deﬁcient
humoral immunity, the increased risk of herpes virus infections in
this population is largely a result of the treatment modalities and
not the disease itself [12,13]. In the recent 2005 study, the APEX
trial, bortezomib vs. high dose dexamethasone therapy alone for
patients with relapsed multiple myeloma was associated with a
statistically signiﬁcant higher incidence, 13 vs. 5% of Herpes zoster
infections [14]. While some authors believe bortezomib therapy is
linked to an increased propensity of HSV reactivation, the evidence
is less clear [12]. In a 2012 study, patients given prophylactic
acyclovir showed a signiﬁcantly lower incidence of varicella zoster
virus (VZV)/complicated HSV while on lenalidomide based
protocols for multiple myeloma [13]. Antiviral prophylaxis with
acyclovir has since been recommended in these patients. However,
our patient did not receive it.
On endoscopic examination, the most frequently affected site is
the distal esophagus, with extensive esophageal involvement often
occurring. Typical ﬁndings include inﬂamed mucosa, often friable
with occasional hemorrhagic changes. Ulcerations are often
numerous and may be superﬁcial or ‘‘punched out,’’ often arranged
in a linear fashion and containing whitish exudates [3]. In a small
review of 38 cases of immunocompetent individuals with HSE,
microscopic ﬁndings consistent with acute and chronic inﬂamma-
tion were present, along with cytopathologic changes and viral
inclusion bodies consistent with herpetic infection were present
68.4% of the time [3]. These non-speciﬁc histologic ﬁndings which
include ballooning degeneration of epithelial cells, multinucleated
giant cells and cowdry type A inclusion bodies can also be found in
other herpes virus infections and are not limited to HSV. In the
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biopsied esophageal tissue which was positive (95.8%) of the time,
followed by immunocytochemistry (87.5%) and histopathology
(68.4%) as previously mentioned [3]. Detection of HSV DNA by PCR
may also be used to improve diagnostic yield in selected cases [16].
Treatment of herpetic esophagitis is rarely required in
immunocompetent individuals. The course is self limited, usually
resolving within a week. Data showing beneﬁt from treatment in
this group is lacking [3,15]. In the immunocompromised host,
older data regarding treatment of HSV esophagitis has come from
mostly small case studies of bone marrow and solid organ
transplant recipients, in whom acyclovir prophylaxis is now
routinely indicated [4,5,19]. Data from larger more recent studies
has been from AIDs patients. In a study of 34 AIDs patients with
conﬁrmed or probable HSV esophagitis treated with acyclovir,
complete clinical responses were achieved in 24 (71%) patients
within a mean of 9 days of treatment and resolution of ulcerations
was endoscopically conﬁrmed for 12 patients. Partial responses
occurred in 3 (9%), with a remaining 6 (18%) lost to follow up and 1
treatment failure [18]. In general, treatment is recommended in
the immunocompromised, while prophylaxis is recommended in
certain heavily immunosuppressed subgroups, as these popula-
tions are at greater risk for disseminated herpes virus infections
and worse outcomes [17,18]. In the case of our patient, although it
may be difﬁcult to establish direct causality, the fact that our
patient promptly responded to anti-viral therapy with complete
resolution of hiccups in 2 days makes a compelling argument as to
HSV being the etiologic agent responsible. This prompt response to
therapy was similar to past cases described in the literature.
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